Granules India Limited has reached a significant milestone with its subsidiary, Granules Life Sciences Private Limited (GLS), securing a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (USFDA). This recognition follows a recent inspection of the Shamirpet manufacturing facility, highlighting the company’s commitment to compliance and quality.
Inspection Overview
The USFDA conducted a thorough inspection at the Shamirpet facility located in Telangana from December 15 to December 19, 2025. The focus was on evaluating adherence to current Good Manufacturing Practices (cGMP) and performing a pre-approval inspection (PAI) of oral solid dosage operations. After completing the inspection, the USFDA released the Establishment Inspection Report (EIR), confirming that the inspection concluded without any recommended regulatory actions.
Understanding VAI Classification
Receiving a VAI classification means that while some observations may have been noted during the inspection, they are not severe enough to prompt enforcement actions from the regulator. This status indicates that Granules India is maintaining a satisfactory level of compliance with regulatory standards.
Commitment to Quality
Dr. Krishna Prasad Chigurupati, Chairman and Managing Director, commented on the significance of the VAI classification, indicating it as a step forward for the company. He reiterated the importance of upholding quality standards across all manufacturing sites, emphasizing an ongoing commitment to excellence.
Enhancing Manufacturing Capabilities
This recent classification strengthens Granules India’s finished dosage manufacturing capabilities. It allows for multi-site manufacturing of approved products, thereby enhancing operational flexibility and efficiency. The ability to produce at multiple locations is vital for meeting the demands of a dynamic market.
Global Presence and Regulatory Compliance
Headquartered in Hyderabad, Granules India is a vertically integrated pharmaceutical manufacturer. The company specializes in active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosage forms. With operations extending to over 80 countries and a clientele of more than 300 customers, Granules India has established a strong global presence.
Focus on Quality and Expansion
Granules India has received numerous regulatory approvals from prestigious authorities, including the USFDA and EU GMP. This underscores the company’s unwavering focus on quality, compliance, and strategic expansion into regulated markets. The recent VAI status further reinforces its commitment to these principles.
Future Prospects
As Granules India continues to navigate the complex pharmaceutical landscape, the VAI classification is expected to bolster its reputation and operational capabilities. The company is poised for growth, with a focus on maintaining high standards and adapting to the evolving needs of the industry.
Key Takeaways
- Granules Life Sciences obtained VAI status from the USFDA after a successful inspection.
- The inspection evaluated compliance with cGMP and focused on oral solid dosage operations.
-
VAI classification indicates satisfactory compliance without enforcement actions required.
-
This achievement enhances the company’s manufacturing capabilities and operational flexibility.
-
Granules India boasts a robust global presence in pharmaceutical manufacturing.
In conclusion, Granules India’s achievement of VAI status marks a pivotal moment for the company, reflecting its dedication to maintaining high-quality manufacturing standards. As it continues to expand and adapt, this recognition positions it well for future success in the pharmaceutical industry.
Read more → medicaldialogues.in